MetaCap

MAIA Biotechnology (MAIA) vs Polaryx Therapeutics (PLYX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

MAIA Biotechnology is the larger company by market cap ($68.5 million vs $66.3 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

MAIA-42.78%PLYX-96.20%
+31%-36%-102%
Feb 2, 20261 yearNov 20, 2026
MAIA-43.65%PLYX-85.07%
+20%-35%-90%
Feb 2, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

MAIA versus PLYX key metrics
MetricMAIAPLYX
Share price$1.11$1.33
Market cap$68.54M$66.30M
1-day change-2.63%-11.92%
YTD return-27.45%—
1-year return+21.71%—
EPS (TTM)$-0.47$-0.18
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-22.40M$-8.98M
52-week high$3.19$48.91
52-week low$0.895$1.30
Distance from 52-week high-65.20%-97.28%
Analyst consensusnonenone
Avg. price target upside+981.08%+463.91%
Average volume524.29K36.42K
Shares outstanding61.75M49.85M
Employees132
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About MAIA Biotechnology

MAIA stock →

MAIA Biotechnology, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the development of targeted immunotherapies for cancer. Its lead product Ateganosine, a telomere-targeting agent currently in clinical development to evaluate its activity in Non-Small Cell Lung Cancer (NSCLC).

Health Care · Biotechnology: Pharmaceutical Preparations · 13 employees

About Polaryx Therapeutics

PLYX stock →

Polaryx Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of disease-modifying therapies for rare and pediatric lysosomal storage disorders in the United States. Its pipeline includes PLX-100, a preclinical stage orally administrable combination therapy; PLX-200, a repurposed oral small molecule for the treatment of LSDs; PLX-300, a preclinical stage orally administrable combination therapy; and PLX-400, a preclinical stage novel gene therapy candidate.

Health Care · Biotechnology: Pharmaceutical Preparations · 2 employees

MAIA vs PLYX FAQ

Which is bigger, MAIA Biotechnology or Polaryx Therapeutics?

MAIA Biotechnology (MAIA) is larger, with a market capitalization of $68.54M compared with $66.30M for Polaryx Therapeutics (PLYX).

Are MAIA Biotechnology and Polaryx Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons